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Background/Aims 
Opioids cause gastrointestinal (GI) dysmotility, decrease gut secretion, and affect gut sphincters. Symptoms of opioid-induced bowel 
dysfunction may be alleviated by peripherally acting opioid antagonists like naloxegol, but detailed knowledge on GI effects of this 
drug is lacking. We hypothesized that naloxegol, compared to placebo, would reduce GI transit time and colonic fecal volume in 
opioid-treated healthy participants. 
Methods
We conducted a randomized, double-blinded, single-center, 2-way cross-over study in 24 healthy males, randomized to a 6 day 
treatment period of oxycodone (15 mg twice a day) co-administered with either naloxegol (25 mg once a day) or matching placebo. 
Participants swallowed an electromagnetic capsule which determined GI transit times. Colonic fecal volume was quantified with 
magnetic resonance imaging both pre-treatment and post-treatment.
Results
Naloxegol reduced total GI transit time by 21% (56 hours vs 71 hours, P = 0.02) and colonic transit time by 23% (45 hours vs 59 
hours, P < 0.01), compared to placebo. However, no difference in colonic fecal volume was found (818 mL vs 884 mL, P = 0.20).
Conclusions
Short-term administration of naloxegol in healthy participants reverses the retardation of total GI and colonic transit induced by 
oxycodone. This supports the use of naloxegol in the treatment of GI side effects to opioid treatment, and add knowledge to the 
current understanding of mechanisms behind peripherally-acting opioid antagonists.
(J Neurogastroenterol Motil 2019;25:602-610)
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Introduction  
Opioids are commonly prescribed to treat pain of moderate 
to severe intensity. However, opioid treatment may induce a wide 
range of severe and bothersome gastrointestinal (GI) side effects, 
collectively termed opioid-induced bowel dysfunction (OIBD). 
The pathophysiology behind OIBD rely on opioid binding of 
peripheral μ-opioid receptors in the enteric nervous system. This 
leads to inhibition of neurotransmitter release in the enteric neurons, 
which diminishes local propulsive reflexes, increases sphincter tone, 
and ultimately causes dysmotility. Additionally, stasis of luminal 
content, and the fact that opioids inhibit vasoactive intestinal peptide 
release, induce excessive passive absorption of fluids.1 Clinically this 
leads to dry, hard stools accumulating in the colon, causing pro-
longed transit time.2 Thus, the most common and burdensome part 
of the OIBD complex is constipation, which is reported by 40-70% 
of all long-term opioid users.3 
OIBD significantly deteriorates patients’ quality of life, and 
imposes substantial cost to society.4-6 Recommended treatment 
strategies to alleviate these GI side effects of opioids rely on dietary 
changes, stool softeners and laxatives.7 However, these treatment 
options do not target the underlying pathophysiology of OIBD. 
Hence, the use of peripherally acting μ-opioid receptor antagonists, 
eg, naloxegol, has become increasingly recognized for inclusion in 
OIBD treatment algorithms.8 Naloxegol, a polymer conjugate of 
the opioid antagonist naloxone, antagonizes opioid receptors in the 
GI tract, while preserving centrally mediated analgesia.9 Until now, 
most studies have focused on the safety and tolerability of nalox-
egol,10,11 as well as efficacy in terms of reduction in weekly sponta-
neous bowel movement frequency in opioid-treated patients and 
healthy participants.12-14 However, there is a need to elucidate the 
more detailed underlying mechanisms of naloxegol, to add informa-
tion on how this type of drug works to relieve symptoms of OIBD. 
Employing an experimental OIBD model, we have previously 
shown that a 5-day treatment of oxycodone prolong GI transit time, 
increase colonic volume, and cause subjectively assessed symptoms 
of OIBD.2,15 The present study is a continuation of a previously 
published paper where we demonstrated that naloxegol improved 
the recto-anal inhibitory reflex and reduced GI symptoms in an ex-
perimental model of OIBD.16 In the present study, we hypothesized 
that naloxegol, compared to placebo, would reduce GI transit time 
and fecal volume in the colon of healthy participants receiving oxy-
codone. The corresponding aims are to assess total GI transit time, 
gastric emptying, small bowel transit time and colonic transit time 
as primary endpoints; segmental colonic transit times, total and seg-
mental colonic fecal volumes as secondary endpoints, during both 
treatments. 
Materials and Methods  
This study is part of a larger protocol that also evaluated 
the effect of naloxegol on anal sphincter function and GI symp-
toms. Thus, some of the presented methods have been published 
previously.16 The full protocol is registered in ClinicalTrials.
gov (EudraCT No. 2015-000419-42). The Danish Medicines 
Agency (Reference No. 2015021429) and The North Denmark 
Region Committee on Health Research Ethics (Reference No. 
N-20150014) approved the protocol, and the study was carried out 
in compliance with the European Community rules of Good Clini-
cal Practice, and the International Conference of Harmonization.
Experimental Design
This randomized, double-blinded, cross-over study was 
conducted from August 2015 to May 2016 at the Mech-Sense 
research laboratories, Department of Gastroenterology and Hepa-
tology, Aalborg University Hospital, Denmark. The sample size 
calculation was based on the variance of total GI transit time as 
reported in a previous study17 where a 12-hour difference in transit 
time was found (SD, 9.6 hours). Including this, with a power of 
95% and and α at 0.05 in a 2-sided test, a sample size of 19 partici-
pants were found appropriate. To allow for missing data, a sample 
size of 24 participants was chosen. Randomization was achieved 
using a computer-generated block-randomization list, and mirror-
randomization was used for replacement of dropouts. Eligible 
participants were opioid naïve healthy men of Northern European 
descent, aged 20 years to 60 years. Key exclusion criteria were use of 
prescription medication, history of substance- or alcohol abuse, and 
smoking. Participants were invited to a screening visit within 14 
days of start of the first treatment period, in which they gave written 
informed consent. 
The study consisted of two 6 day treatment periods, and a ≥ 14 
day washout period was applied (Fig. 1). Treatment periods began 
with baseline (pre-treatment) measurements of colonic fecal volume 
using magnetic resonance imaging (MRI), and GI symptoms us-
ing self-assessed questionnaires. Hereafter the first dose of oxyco-
done was administered. Participants received envelopes for home-
administration of either: prolonged-release oxycodone tablets (10 
mg twice a day [bid] on day 1, 15 mg bid on days 2-5, and 15 mg 
once a day [qd] on day 6) and naloxegol tablets (25 mg qd on days 
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2-6) (oxycodone + naloxegol), or prolonged-release oxycodone and 
matching placebo tablets (oxycodone + placebo). Medication was 
delivered by The Hospital Pharmacy at Aalborg University Hospi-
tal, Denmark. On day 2, the 3D-Transit system belt was mounted at 
home, and the 3D-Transit electromagnetic capsule was swallowed. 
Throughout days 2-5, participants wore the 3D-Transit belt and 
self-administrated the medication on scheduled time points. The 
treatment periods terminated at day 6 (post-treatment), in which 
the belt was detached at the hospital and assessment of colonic fecal 
volume was repeated. 
Gastrointestinal Transit Time
Technical specifications of the 3D-Transit system are described 
in detail elsewhere.18 In the morning of day 2, participants mounted 
the abdominal belt containing the recording detector plate, and 
after ingestion of a standardized meal (nutrition bar; 375 kcal, 11.4 
g fat, and 1.8 g fiber) the 3D-Transit electromagnetic capsule was 
swallowed with a glass of water. Participants were instructed to wear 
the abdominal belt throughout the rest of the treatment period, only 
interrupted when showering. They were able to perform their nor-
mal daily activities, however, hard physical work was not allowed. 
The recordings stopped when participants arrived at the research 
department in the morning of day 6. Here, retention or expulsion 
of the capsule was confirmed by monitoring emitting signals from 
the capsule in real-time using 3D-Transit analysis software (Moti-
lis Medica SA, Lausanne, Switzerland). Gastric emptying, small 
bowel transit time, and colonic transit time were determined manu-
ally using the analysis software, by evaluating changes in bowel 
contraction frequencies observed on capsule rotation graphs, time-
frequency map of contractions, and 2D images of capsule position, 
as described previously.18 Total GI transit time was defined as the 
time between ingestion and expulsion of the capsule. If the capsule 
was retained, the time of the last confirmed capsule signal was used 
as the earliest possible expulsion time. Transit times of the 4 colonic 
segments (cecum/ascending colon, transverse colon, descending co-
lon, and rectosigmoid colon) were assessed based on algorithms of 
capsule trajectory incorporated into a custom MATLAB (R2015b 
version 8.6; MathWorks, Inc, Natick, MA, USA) application, as 
earlier validated.15
Colonic Fecal Volume
Participants were always scanned in a fasting state in the 
morning. No restrictions on bowel movements were made prior 
to scanning, and no bowel preparations were used. 3D-Transit cap-
sules are not approved for MRI, which is why imaging was only 
performed on day 6 in participants in which capsule retention was 
ruled out. MRI scans were acquired using a GE 3T scanner (GE 
Signa HDxt, General Electrical, Milwaukee, Wisconsin, USA). 
A coronal image series of the abdomen was obtained using Dixon-
type liver accelerated volume acquisition (LAVA-Flex) water-only 
scans (echo time [TE] = 2.3/4.6, repetition time [TR] = 7.2 mil-
liseconds, in-plane resolution 0.9375 × 0.9375 mm, slice thickness 
4 mm). The entire series were performed during a single inspired 
breath hold of approximately 20 seconds. In total, 35-40 contiguous 
slices were obtained covering the entire colon and rectum. A semi-
automatic in-house data analysis software was used to determine the 
Screening
Morning
Evening
Colon MRI
OXY (10 mg)
OXY (15 mg)
NAL/PLA (25 mg)
OXY (15 mg)
NAL/PLA (25 mg)
OXY (15 mg)
NAL/PLA (25 mg)
OXY (15 mg)
NAL/PLA (25 mg)
OXY (15 mg)
NAL/PLA (25 mg)
3D-Transit start 3D-Transit end
Colon MRI
O (10 mg)XY OXY (15 mg) OXY (15 mg) OXY (15 mg) OXY (15 mg)
Wearing 3D-Transit belt
Day 1
Pre-treatment
Day 2 Day 3 Day 4 Day 5 Day 6
Post-treatment
Randomization
Oxycodone + naloxegol
Oxycodone + placebo
Oxycodone + naloxegol
Oxycodone + placebo
A
B
Figure 1. Study design (A) and timeline (B) for a treatment period. MRI, magnetic resonance imaging; OXY, oxycodone; NAL, naloxegol; PLA, 
placebo.
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volume of non-gaseous colonic content (feces) as described in detail 
elsewhere,19,20 and as suggested by another research group using a 
similar approach.21 In short, regions of interest were manually out-
lined on each image encapsulating the following colonic segments; 
ascending colon (including cecum), transverse colon, descending 
colon, and rectosigmoid colon. A classification approach using k-
means clustering was applied to refine the segmentation of the co-
lon, and calculate the fecal volume.
Gastrointestinal Symptoms
Results from the Patient Assessment of Constipation Symptom 
(PAC-SYM) questionnaire and the Bristol Stool Form Scale have 
been published previously16 and were used for analysis of associa-
tion between subjective and objective measures. 
Statistical Methods
Data were assessed for normality by graphical and numeri-
cal methods (histograms, Q-Q plots, and Shapiro-Wilk tests) and 
handled accordingly. Total/segmental transit times and data on 
capsule retention were analyzed by Wilcoxon signed rank sum tests 
(Bonferroni-adjusted for multiple comparisons). Segmental colonic 
fecal volumes were analyzed by repeated measures mixed models. 
Bonferroni-adjusted post hoc tests were applied for all mixed mod-
els in which an overall significant difference was found. Pearson’s 
correlation coefficient was used to identify associations between GI 
symptoms (reported previously16) and (1) effects on GI transit time 
and (2) effects on colonic fecal volumes. All reported P-values were 
2-tailed and values < 0.05 were considered statistically significant. 
Data were analyzed using Stata version 14.0 (StataCorp LP, Texas, 
TX, USA). Descriptive results are presented as means ± SD.
Results  
One participant was excluded after the first treatment period 
(due to non-adherence to the study protocol). He was replaced, and 
thus, 24 participants completed both treatment periods (Fig. 2). 
Age ranged from 20-46 years, and body mass index ranged from 
20.9-31.5 kg/m2. 
Gastrointestinal Transit Time
Total and segmental GI transit times are presented in Table 1. 
Recordings of gastric emptying, small bowel transit time, colonic 
transit time, and total GI transit time were obtained in all partici-
pants in both treatment periods (48 recordings in total). However, 
Figure 2. Flowchart for disposition of participants. 
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it was not possible to determine segmental colonic transit times in 
12/48 recordings (7 in the oxycodone + placebo treatment and 5 
in oxycodone + naloxegol), due to either poor data quality and/or 
inadequate data due to capsule battery loss. This left 36 recordings 
for further analysis of segmental colonic transit. Capsule retention 
on day 6 occurred in 3/24 recordings during oxycodone + nalox-
egol treatment and 8/24 during oxycodone + placebo (P = 0.084). 
Naloxegol reduced oxycodone-induced prolongation of total GI 
transit time by 21% (56.8 ± 21.3 hours vs 71.3 ± 19.8 hours; P = 
0.016, and colonic transit time by 23% (45.0 ± 21.1 hours vs 59.7 
± 19.3 hours; P =0.006), compared to placebo. Post-hoc analysis 
revealed the reduction in colonic transit time by naloxegol to be con-
fined to the rectosigmoid segment (60%; 9.2 ± 8.6 hours vs 23.0 
± 13.6 hours; P = 0.047). There was no difference between oxy-
codone + naloxegol and oxycodone + placebo treatments in either 
gastric emptying (5.3 ± 4.8 hours vs 3.4 ± 3 hours; P = 0.144) or 
small bowel transit time (7.4 ± 2.6 hours vs 7.9 ± 5.4 hours; P = 
0.648). 
Colonic Fecal Volume
Eleven out of 96 MRI scans were not performed post-treat-
ment due to capsule retention, 4 scans were missed due to technical 
problems with the MRI scanner, and 2 scans were discarded due 
to insufficient data quality. Thus, 80 scans were left for further 
analysis, in which 23 pre-treatment scans were obtained for each 
treatment, and 15/19 post-treatment scans were obtained for oxy-
codone + naloxegol and oxycodone + placebo treatment, respec-
tively. Measures of colonic fecal volume are presented in Table 2. 
Table 1. Total and Segmental Gastrointestinal Transit Times
Variables (hr) Oxycodone + naloxegol Oxycodone + placebo P-value
Gastric emptying 5.3 (3.1-7.4) 3.4 (3.4- 4.5) 0.432
Small bowel transit time 7.4 (6.3-8.5) 7.9 (5.4-9.6) > 0.999
Colonic transit time 45.0 (35.5-53.0) 59.7 (52.0-68.3) 0.018
    Ascending colon 16.4 (8.8-23.9) 12.2 (4.9-19.0) 0.452
    Transverse colon 10.1 (5.3-15.0) 10.6 (6.8-14.4) 0.231
    Descending colon 4.6 (1.7-7.4) 9.0 (5.0-13.0) 0.104
    Rectosigmoid colon 9.2 (5.0-13.4) 23.0 (16.0-30.0) 0.047
Total gastrointestinal transit time 56.8 (48.0-65.7) 71.3 (63.0-79.5) 0.016
Data are presented as means (95% confidence intervals). n = 48 recordings (24 in each treatment) to determine gastric emptying, small bowel transit time, colonic 
transit time, and total gastrointestinal transit time. n = 36 recordings (19 in the naloxegol treatment and 17 in placebo) to determine segmental colonic transit times.
Table 2. Total and Segmental Colonic Fecal Volumes (in mL)
Segment Assessment Oxycodone + naloxegol Oxycodone + placebo P-valuea
Ascending colon Pre-treatment 227 (196-258) 230 (199-261) 
Post-treatment 281 (236-326) 301 (257-345) > 0.999
Difference 54 (3-105) 71 (22-120)
Transverse colon Pre-treatment 172 (132-211) 188 (152-224) 
Post-treatment 232 (184-281) 244 (194-295) > 0.999
Difference 60 (2-118) 56 (–2-116) 
Descending colon Pre-treatment 95 (68-122) 93 (64-122) 
Post-treatment 154 (116-192) 134 (96-172) > 0.999
Difference 76 (33-119) 41 (2-84) 
Rectosigmoid colon Pre-treatment 139 (114-163) 168 (137-199) 
Post-treatment 149 (114-185) 203 (148-259) 0.442
Difference 10 (–30-40) 35 (–22-93) 
Total colon Pre-treatment 634 (547-721) 680 (590-770) 
Post-treatment 818 (686-950) 884 (739-1030) 0.201
Difference 204 (47-361) 184 (37-331) 
aPre-treatment vs post-treatment.
Data are presented as means (95% confidence intervals). n = 23 pre-treatment scans for each treatment period. n = 19 and 15 post-treatment scans for oxycodone + 
naloxegol and oxycodone + placebo treatment period, respectively. 
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Fecal volume increased post-treatment, compared to pre-treatment, 
in both treatments (29%, 818 ± 273 mL vs 634 ± 200 mL for 
oxycodone + naloxegol, P < 0.001; 30%, 884 ± 262 mL vs 680 
± 207 mL for oxycodone + placebo, P < 0.001). No significant 
difference in volume post-treatment was found between treatments 
(884 ± 262 mL vs 818 ± 273 mL, P = 0.201. 
Associations to Gastrointestinal Symptoms
There were no associations between subjectively reported GI 
symptoms and segmental transit times or colonic fecal volumes (all 
Pearson’s r < ± 0.5; all P > 0.05).
Discussion  
This study investigated the effect of naloxegol on GI transit 
times and colonic fecal volume during experimentally-induced 
OIBD. Naloxegol reduced total GI and colonic transit times dur-
ing oxycodone treatment, whereas gastric emptying and small bowel 
transit time were unaffected. Naloxegol did not affect fecal volume 
in the colon. 
As the study was part of a larger protocol that also evaluated 
the effect of naloxegol on anal sphincter function and GI symptoms 
presented previously,16 an overview of results are presented in Table 
3.
It was previously demonstrated that oxycodone prolonged total 
and segmental GI transit times in a trial employing a similar study 
design.15 This indicates that the chosen dose of oxycodone (ie, 30 
mg per day) and the length of treatment was sufficient to establish 
a model of OIBD. The present results support a previous study 
where naloxegol reduced morphine-induced prolongation of total 
GI transit time, as assessed with the lactulose hydrogen breath 
test.22 Additionally, our findings are in line with a previous study 
investigating another commercialized peripherally acting μ-opioid 
receptor antagonists, alvimopan (only approved in the United States 
for post-operative ileus), in which a dosage of 12 mg bid reversed 
codeine-induced prolongation of small bowel and colonic transit.23 
In contrast, methylnaltrexone (a peripherally acting μ-opioid recep-
tor antagonist only available as subcutaneous injection in advanced 
OIBD) had no effect on codeine-induced prolongation of colonic 
transit.24 For the latter, the authors question whether a higher dosage 
of methylnaltrexone may be needed to produce a detectable effect 
on transit in opioid-naïve participants. It is important to recognize 
that, compared to eg, radioscintigraphy, the 3D-Transit system es-
sentially tracks a single solid marker throughout the GI tract, and 
not necessarily the stool itself. Furthermore, a wide variation in GI 
transit times measured with the 3D-Transit has been found, with 
a median day-to-day variation in total GI transit time of 10 hours 
(range of 3-25 hours), between capsules ingested at the same time 
of the morning the following day.18 Thus, the difference in total and 
segmental GI transit time between oxycodone + naloxegol and oxy-
codone + placebo treatment needs to be interpreted with caution. 
However, the 3D-Transit system was the best method of choice as 
it holds several advantages compared to other available tools.25 In 
addition, transit times obtained from the 3D-Transit system has 
been validated against radiopaque markers, a well-established and 
commonly used method.26 The normal increase in propagating mo-
tor patterns, including high-velocity propagating sequences (also 
recognized as mass movements) occurring after a meal, are also 
diminished in patients with slow transit constipation.27 These patho-
logical mechanisms may explain why naloxegol only reduced transit 
time in colon, and not in the stomach and the small bowel. 
There were no associations between subjective assessments of 
constipation and transit times or fecal volumes, and results from an-
other part of the same study also showed that naloxegol did not in-
crease spontaneous bowel movement frequency despite an increase 
in sphincter relaxation (Table 3).16 On the other hand, constipation 
is a subjective phenomenon composed of a series of complaints. 
Although it is often defined by bowel movement––especially in 
epidemiological studies––it is primarily characterized by straining, 
gas, hard consistency of stools, and abdominal discomfort, with in-
frequent bowel movements and bloating both ranking No. 5 on the 
Table 3. Overview of Naloxegol Effects
Outcome Effect
Effects on anal sphincter function
Anal resting pressurea ↔
Sphincter relaxationa ↑
Distensibility of anal canala ↔
Effects on subjective scores
PAC-SYM scoresa ↓
SBM frequencya ↔
SBM stool consistencya ↑
Effects on GI transit and colonic fecal volumes
Total GI transit time ↓
Colonic transit time ↓
Gastric emptying ↔
Small bowel transit time ↔
Fecal volume ↔
aResults from Grønlund et al.16 
PAC-SYM, Patient Assessment of Constipation Symptom; SBM, spontane-
ous bowel movement; GI, gastrointestinal; ↔, unaffected; ↑, increased; ↓, 
decreased by naloxegol. 
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list.28 Similar findings have been found in patients with constipation 
where spontaneous bowel movement frequency correlated poorly 
with transit time.29 In summary, no significant associations between 
subjective and objective measurements were found. However, the 
objective measurements are still relevant as the study was designed 
to investigate the mechanisms of the effect of naloxegol on experi-
mentally induced OIBD, and the objective methods provide us 
with more detailed information on intestinal motility, than the sub-
jective assessments. 
The fact that naloxegol mainly reduced transit time in the 
rectosigmoid part of the colon may relate to alleviation of defeca-
tion problems collectively known as opioid-induced anal sphincter 
dysfunction.30 This dysfunction may be an indirect consequence of 
opioid-induced prolonged transit causing increased passive absorp-
tion of fluids, ultimately leading to stools difficult to pass. Also, elici-
tation thresholds for the recto-anal inhibitory reflex have been found 
to be decreased during opioid treatment, and other results from our 
study demonstrated that this effect was reverted by naloxegol (Table 
3).31,16 However, these findings may also have to do with exagger-
ated continence of promoting motility which should be further 
investigated in new studies. Normalization of motility and reduced 
passive absorption of gut fluids may also explain why improvement 
in self-reported stool consistency by naloxegol was found (Table 3).16 
The increase in colonic fecal volume after 6 days of oxycodone 
treatment in both periods verified what has previously been shown.2 
However, a refined method was used to address non-gaseous fecal 
volume only, excluding the volume of the colon wall itself and gas 
within the intestine. Considering that naloxegol reduced colonic 
transit time, it is interesting that no effect on fecal volume was 
found. This may relate to the effect of the assessed drugs on gut se-
cretion. When opioids act on μ-receptors within the enteric nervous 
system, the release of the vasoactive intestinal peptide is blocked, 
ultimately leading to decreased gut secretion.32 Hypothetically, nal-
oxegol may counteract these effects, leading to more watery stool, 
which may be interpreted as a higher fecal load on the MRI images. 
This would ultimately counterbalance the fecal volume to equal that 
of placebo treatment, despite faster GI transit time. This theory is 
supported by, the analysis of other endpoints from the same study 
from our group,16 and a recent study in opioid-treated patients33 
where increased scores of stool consistency (ie, softer stools) were 
found after treatment with naloxegol. However, at the moment, the 
applied MRI-based method does not allow quantification of water 
load in colonic content. Additional refinement of the MRI method 
is needed to provide important knowledge into gut secretion mech-
anisms, and how this is affected by medication. Missed MRI scans 
is a major study limitation, in particular in the 8 cases in which the 
capsule in the placebo arm was retained. In itself, capsule retention 
indicates constipation, and it is likely that these participants would 
also show the most pronounced increase in fecal volume. Hence, 
the data on colonic fecal volume may be systematically underesti-
mated, and the results should therefore be interpreted with caution. 
Also, it would have been commendable to perform MRI scans on 
each day, however this was not feasible. As the post-treatment MRI 
scan was conducted after assessment of transit time, information 
from days in-between 1 and 6 is unavailable. 
Confounding factors like other GI diseases, concomitant drug 
use, and depression are difficult to avoid in clinical studies. In an 
experimental OIBD model applied in healthy persons, these factors 
are profitably controlled for, however, the experimental setting may 
not completely mirror the clinical picture of chronic opioid users. 
Therefore, statistical significance in the experimental setting may 
not translate to clinical relevance. However, one could also speculate 
that the observed effects of naloxegol on transit time and symptoms 
would be even more pronounced in patients with OIBD.
So far, the clinical benefit of naloxegol to treat OIBD has 
predominantly been based on the reduction in spontaneous bowel 
movement frequency. To gain new insights into the underlying ef-
fects of naloxegol, the current study evaluated its effects on total and 
segmental GI transit times, and colonic fecal volume employing the 
3D-Transit system and a novel MRI technique in opioid-treated 
heathy participants. Naloxegol reduced total GI transit time, and 
colonic transit time with the main effect on rectosigmoid transit. 
Taken into account that naloxegol treatment also reduced GI symp-
toms and improved stool consistency (Table 3),16 our results support 
the use of naloxegol in prevention and treatment of OIBD. Also, 
these findings add knowledge to the current understanding of pe-
ripherally acting μ-opioid receptor antagonist effects on the opioid-
affected GI tract.
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